Aurinia Pharmaceuticals Inc., a biopharmaceutical company, focuses on delivering therapies to treat autoimmune diseases with unmet medical needs in the United States. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Current Quarter	$0.21	Next Quarter	$0.18
Current Year	$0.78	Next Year	$0.85
QoQ Growth	-14.3%	YoY Growth	+9.0%
3Y EPS CAGR	+0.0%	Target Price	$16.71
Consensus	Buy	Upside	+5.4%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AUPH	$15.85	-0.19%	959.59K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AUPH	$15.85	-0.2%	959.59K
3
4
5
6

AUPH

AUPH

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Aurinia Pharmaceuticals Inc Data in Excel

Get Aurinia Pharmaceuticals Inc Data in Excel